Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Converting Blood Cells into Therapeutic Approaches for Autoimmune Disease

By BiotechDaily International staff writers
Posted on 31 Jul 2013
Cells from one individual’s blood could be transformed into autoimmune diseases therapy, disorders such as rheumatoid arthritis and Crohn’s disease.

Chang Kim, a professor of comparative pathobiology at Purdue University (West Lafayette, IN, USA), has devised an application to direct the differentiation of T-cells. The technology employs naïve T-cells, immature cells from which all T-cells develop, and stimulates them to become suppressive T-cells that block the development of painful inflammation associated with autoimmune diseases.

Naïve T-cells can be collected from a patient’s blood, treated and then re-injected, according to Prof. Kim, who also is a university faculty scholar and member of Purdue’s Center for Cancer Research and Weldon School of Biomedical Engineering. “These cells are being directed to become a type of cell that is already present in our bodies, where a fine balance between inflammatory T-cells and suppressive T-cells is maintained,” he said. “We are just tipping the scales in favor of suppressive T-cells to reduce inflammation. Because of this there are none of the toxic side effects associated with many immune-suppressive drugs. In addition, cells from one's own body aren’t rejected and remain in the body much longer. Instead of taking a pill every day, this could lead to a treatment administered, for example, every six months.”

Autoimmune diseases occur when the immune system attacks one’s own body instead of fighting off infection from bacteria, viruses, and other foreign cells. An overactive immune system sends T-cells to healthy tissue and organs where they cause inflammation and tissue destruction.

Suppressive T-cells travel to regions of inflammation and inhibit the T-cells there without substantially reducing the number of T-cells in other areas of the body where they are needed for effective immune function, according to Dr. Kim. “Treatment with suppressive T-cells has the potential to be a much more precise and targeted regulation of immune function than what currently exists,” he said. “Treating autoimmune diseases without compromising a patient’s immune system has been a big problem in the field. We need to catch the thief without taking down the house, and this has that potential.”

Prof. Kim discovered that naïve T-cells cultured in the presence of the hormone progesterone can be induced to become suppressive T-cells. This project’s articles were published July 2013 in the Journal of Immunology and the European Journal of Immunology. The group also filed a patent based on this work.

Laboratory mice research showed that about 500,000 suppressive T-cells are needed to have an effect on inflammation, according to Prof. Kim. “More work needs to be done to determine the appropriate dosage of cells for a human patient, but the amount of blood many people regularly donate would likely yield multiple treatments,” he said.

In the next phase, Prof. Kim plans to explore at the molecular level how progesterone causes the cells to differentiate into suppressive T-cells and to discover the proteins and protein receptors involved. He stressed that a better determination of the molecular regulation of these cells could lead to a way to control their differentiation and function without using progesterone.

Related Links:

Purdue University




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.